Experience

Hengrui Pharmaceuticals Announces License Agreement With Merck KGaA

April 8, 2025

Cooley advised Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, on its exclusive license agreement with Merck KGaA, Darmstadt, Germany for the commercialization in mainland China of SHR7280, an oral small-molecule gonadotropin-releasing hormone receptor antagonist, for indications including medical-assisted reproduction and gynecology.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Freddy Yip
Associate, Hong Kong
Caroline Vu
Special Counsel, Palo Alto
Letian Wei
Legal Consultant, Shanghai
Marc Suskin
Partner, New York
Sharon Connaughton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Rebecca Ross
Special Counsel, Washington, DC
Bin Wang
Special Counsel, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Natasha Leskovsek
Of Counsel, Washington, DC
Jiqiang Lin
Associate, New York
Amanda Pacheco
Associate, Palo Alto

Related Practices & Industries

Puhe BioPharma Announces Global License Agreement With Bayer

March 26, 2025

Cooley advised Puhe BioPharma, a biotechnology company dedicated to the research and development of innovative small-molecule precision therapeutics, on its global license agreement with Bayer for Puhe BioPharma’s oral, small-molecule protein arginine methyltransferase 5 inhibitor that selectively targets metabolic enzyme 5’-deoxy-5’-methylthioadenosine phosphorylase-deleted tumors.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Freddy Yip
Associate, Hong Kong
David Burns
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Amanda Pacheco
Associate, Palo Alto

Related Practices & Industries

Chimerix Announces Acquisition by Jazz Pharmaceuticals for $935 Million

March 5, 2025

Cooley advised Chimerix (Nasdaq: CMRX), a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, on its definitive agreement to be acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) for $8.55 per share in cash – totaling approximately $935 million.

Read more

Related contacts

Jason Kent
Partner, New York
Kevin Cooper
Partner, New York
Nathan Baum
Special Counsel, New York
Jamie Leigh
Partner, San Francisco
Izzy Lubarsky
Partner, New York
Susan Choy
Associate, New York
Charlotte Yin
Associate, New York
Angela Kim
Associate, New York
Jane Adams
Partner, San Diego
Christophe Beauduin
Partner, New York
Ross Eberly
Partner, Santa Monica
Stella Sarma
Partner, Brussels
Megan Arthur Schilling
Partner, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Juliana Finley
Associate, Santa Monica
Elizabeth Galvin
Associate, Boston
Carly E. Gibbons
Associate, Chicago
Nathaniel Hearn Jr.
Associate, Chicago
Calvin Lee
Associate, New York
Joseph Perry
Associate, Reston
Greg Reith
Associate, Washington, DC
Freddy Yip
Associate, Hong Kong
Drue Anne Koons
Paralegal Specialist, San Diego

Related Practices & Industries

Alumis Announces Merger With ACELYRIN

February 6, 2025

Cooley advised Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, on its definitive agreement with ACELYRIN to merge in an all-stock transaction.

Read more

Related contacts

Jamie Leigh
Partner, San Francisco
David Peinsipp
Partner, San Francisco
Ben Beerle
Partner, San Francisco
Kristin VanderPas
Partner, San Francisco
Polina A. Demina
Special Counsel, New York
Sangitha Palaniappa
Associate, Palo Alto
Christine Turner
Associate, Colorado
Shaun (Tianjie) Wang
Associate, New York
Megan Browdie
Partner, Washington, DC
Lauren Creel
Partner, Palo Alto
Ross Eberly
Partner, Santa Monica
Stephanie Gentile
Partner, New York
Sarah Lightdale
Partner, New York
Phil Mitchell
Partner, New York
Jeremy Morrison
Partner, Washington, DC
Alessandra Murata
Partner, Palo Alto
Jennifer Raab
Partner, Palo Alto
Patrick Van Eecke
Partner, Brussels
Natasha Leskovsek
Of Counsel, Washington, DC
Julia R. Brinton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Caroline Vu
Special Counsel, Palo Alto
Christopher Andrews
Associate, New York
Dannielle Antone
Associate, San Francisco
Tamara Chin Loy
Associate, Washington, DC
Navya Dasari
Associate, New York
Joshua Elefant
Associate, Palo Alto
Winda Fung
Associate, Santa Monica
Gary Warren Hunt III
Associate, Washington, DC
Wyatt Kernell
Associate, Colorado
Kristina Krasnikova
Associate, Palo Alto
Sunny J. Levine
Associate, Colorado
Amanda Lindner
Associate, New York
Jayne M. Munger
Associate, New York
Julianne Orr
Associate, San Francisco
Michael Pelle
Associate, New York
Breanna Qin
Associate, Palo Alto
Bartholomäus Regenhardt
Associate, Brussels
Jesse Schulman
Associate, Colorado
Freddy Yip
Associate, Hong Kong
Isabella Ysebrands
Associate, San Francisco

Related Practices & Industries

InnoCare and KeyMed Jointly Announce License Agreement With Prolium

January 20, 2025

Cooley represented Beijing Tiannuo Jiancheng Pharmaceutical Technology, a joint venture of a subsidiary of InnoCare Pharma (HKEX: 09969; SSE: 688428) and a subsidiary of KeyMed Biosciences (HKEX: 02162), in connection with a joint exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02 (CM355), a CD20xCD3 bispecific antibody.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Freddy Yip
Associate, Hong Kong
Michael Shen
Special Counsel, Shanghai
Ivy Wang
Associate, Shanghai
Letian Wei
Legal Consultant, Shanghai
Jameson Davis
Associate, Boston
Robert Eisenbach
Of Counsel, San Francisco
Xander Lee
Partner, Santa Monica
Chen Chen
Special Counsel, Palo Alto
Bin Wang
Special Counsel, Palo Alto
Monica Xu
Special Counsel, Shanghai

Related Practices & Industries

View more

Admissions and credentials

Hong Kong